IGC Pharma (IGC) Receivables (2011 - 2026)

IGC Pharma (IGC) has reported Receivables for 16 consecutive years, with $694000.0 the latest figure, recorded in Q1 2026.

• On a quarterly basis, Receivables rose 1941.18% year-over-year to $694000.0 in Q1 2026; TTM through Mar 2026 was $694000.0, a 1941.18% increase from a year earlier, with the FY2026 full-year figure at $694000.0, down 2.8% from the prior year.
• Receivables was $694000.0 for Q1 2026 at IGC Pharma, up from $679000.0 in the prior quarter.
• Over five years, Receivables peaked at $1.2 million in Q2 2023 and troughed at -$272000.0 in Q1 2024.
• A 5-year average of $655294.1 and a median of $714000.0 in 2024 frame the typical range for Receivables.
• Across the five-year window, Receivables slumped 263.86% in 2024 and jumped 1941.18% in 2026, its largest moves.
• Over 5 years, Receivables stood at $1.0 million in 2022, then grew by 3.59% to $1.0 million in 2023, then slipped by 29.87% to $728000.0 in 2024, then retreated by 6.73% to $679000.0 in 2025, then climbed by 2.21% to $694000.0 in 2026.
• The last three Receivables figures came in at $694000.0 (Q1 2026), $679000.0 (Q4 2025), and $711000.0 (Q3 2025), per Business Quant data.